BCM
OBIO icon

Bridgeway Capital Management’s Orchestra BioMed OBIO Stock Holding History

Bridgeway Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$300K Buy
70,600
+45,600
+182% +$194K 0.01% 935
2025
Q4 		$104K Hold
25,000
– – ﹤0.01% 1121
2025
Q3 		$62K Hold
25,000
– – ﹤0.01% 1153
2025
Q2 		$67K Buy
+25,000
New +$73K ﹤0.01% 1114

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bridgeway Capital Management's OBIO Position: Q1 2026 in Review

Bridgeway Capital Management increased its Orchestra BioMed (OBIO) stake by 182% in Q1 2026, buying an estimated $194K and bringing the position to 70,600 shares worth $300K. The position accounts for 0.01% of the portfolio, ranked #935.

Bridgeway Capital Management first reported a position in OBIO in Q2 2025 and has held it in 4 quarters since. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Bridgeway Capital Management held 70,600 shares of Orchestra BioMed worth $300K as of Q1 2026.
  • Bridgeway Capital Management bought 45,600 Orchestra BioMed shares in Q1 2026, an estimated $194K.
  • Orchestra BioMed made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #935 holding.
  • Bridgeway Capital Management first reported a position in Orchestra BioMed in Q2 2025 and has held it in 4 quarters since.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.